Guidance for applicants on how to submit ePI in centralised procedures
Submitted by Anonymous (not verified) on 4 September 2026 - 14:02
Guidance for applicants on how to submit ePI in centralised procedures
Electronic product information (ePI)
Submitted by Anonymous (not verified) on 4 September 2026 - 14:00
Electronic product information (ePI)
Referral: Parenteral iron-containing medicinal products, ferric carboxymaltose,ferric derisomaltose,ferric gluconate,ferric hydroxide polymaltose complex,iron dextran,iron sucrose Article 31 referrals Procedure started
Submitted by Anonymous (not verified) on 4 September 2026 - 13:00
Referral: Parenteral iron-containing medicinal products, ferric carboxymaltose,ferric derisomaltose,ferric gluconate,ferric hydroxide polymaltose complex,iron dextran,iron sucrose Article 31 referrals Procedure started
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 31 August - 3 September 2026
Submitted by Anonymous (not verified) on 4 September 2026 - 13:00
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 31 August - 3 September 2026
Executive Director's speech at Duke-NUS Medical School in Singapore
Submitted by Anonymous (not verified) on 4 September 2026 - 13:00
Executive Director's speech at Duke-NUS Medical School in Singapore
COVID-19 medicines
Submitted by Anonymous (not verified) on 4 September 2026 - 12:47
COVID-19 medicines
Framework for interaction with pharmaceutical industry stakeholders
Submitted by Anonymous (not verified) on 4 September 2026 - 11:00
Framework for interaction with pharmaceutical industry stakeholders
Pharmaceutical industry: Getting involved in EMA activities
Submitted by Anonymous (not verified) on 4 September 2026 - 11:00
Pharmaceutical industry: Getting involved in EMA activities
Scientific advice and protocol assistance
Submitted by Anonymous (not verified) on 4 September 2026 - 11:00
Scientific advice and protocol assistance
Human medicines European public assessment report (EPAR): Repatha, evolocumab, Date of authorisation: 17/07/2015, Revision: 28, Status: Authorised
Submitted by Anonymous (not verified) on 4 September 2026 - 10:26
Human medicines European public assessment report (EPAR): Repatha, evolocumab, Date of authorisation: 17/07/2015, Revision: 28, Status: Authorised